12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Scenesse afamelanotide: Phase II started

Clinuvel began the double-blind, placebo-controlled, Singaporean Phase II CUV103 trial to compare 16 mg Scenesse every 4 weeks plus twice-weekly narrow-band ultraviolet B (NB-UVB) light vs. NB-UVB light alone for 7 months in about 60 patients with nonsegmental vitiligo. An MAA for Scenesse is under EMA review for prophylactic...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >